Home
Resources
Diseases
Training
SYSVAC
About
Registry
E-learning courses
News
Events
Network
Vision and Mission
Steering Committee
Map
Meetings
Join us
Home
Resources
Resources
Selected
COVID-19
Human papillomavirus (HPV)
2022
Eastern Mediterranean
Western Pacific
Clear all
Type of publications
NITAG documentation
(11)
Systematic reviews (SYSVAC)
(13)
Topics
Available to download in languages
Regions
Eastern Mediterranean
(3)
Western Pacific
(21)
Americas
(47)
Europe
(38)
South-East Asia
(3)
Countries
Australia
(11)
China
(8)
Jordan
(1)
Pakistan
(1)
Saudi Arabia
(1)
Diseases
COVID-19
(20)
Human papillomavirus (HPV)
(4)
Hepatitis B
(1)
Japanese encephalitis
(1)
Mpox // Monkeypox
(1)
Pneumococcal disease
(2)
Vaccine topics
Acceptance
(7)
Coverage
(1)
Economic aspects
(2)
Efficacy/effectiveness
(2)
Safety
(2)
Target population
Adolescents
(7)
Adults
(9)
All age groups
(3)
Children
(3)
Healthcare workers
(3)
Older adults
(4)
Parents/caregivers
(2)
Publication date
2022
(24)
2023
(8)
2021
(15)
2020
(20)
2019
(2)
2018
(3)
2017
(3)
2016
(1)
2015
(3)
2013
(2)
2011
(1)
2010
(4)
2008
(2)
24 results found
2022
∙
Chen, H. Zhang, X. Lin, G. Gong, F. Hocher, B.
Safety of COVID-19 vaccination in women undergoing IVF/ICSI treatment - Clinical study and systematic review
2022
∙
Zhu, K. Tian, Y. Dong, X. Akinwunmi, B. O. Zhang, C. J. P. Huang, J. Ming, W. K.
The cost-effectiveness of bivalent, quadrivalent, and nine-valent HPV vaccination in Asia: a systematic review
2022
∙
Khabour, O. F.
The COVID-19 vaccine acceptance in Jordan: a meta-analysis and review of the literature
2022
∙
ATAGI
ATAGI recommendations on use of the Pfizer bivalent (Original/Omicron BA.1) COVID-19 vaccine
2022
∙
ATAGI
ATAGI recommendations for a booster dose of the paediatric Pfizer COVID-19 vaccine in children aged 5 to 11 years
2022
∙
ATAGI
COVID-19 vaccination – Guidance on myocarditis and pericarditis after COVID-19 vaccines
2022
∙
ATAGI
ATAGI statement on use of the Moderna bivalent Original/Omicron vaccine
2022
∙
ATAGI
Novavax vaccine for adolescents aged 12-17 years
2022
∙
ATAGI
ATAGI recommendations for use of Pfizer COVID-19 vaccine as a booster dose in adolescents aged 16-17 years
2022
∙
ATAGI
ATAGI recommendations on the use of a booster dose of COVID-19 vaccine
Home
Resources
Diseases
Training
SYSVAC
News
Events
Network
Sign in / Register